71,833 results match your criteria Neutropenia


Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel.

Invest New Drugs 2022 Jun 27. Epub 2022 Jun 27.

Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ABCC10/MRP7, an ATP-binding cassette (ABC) transporter, has been implicated in the extracellular transport of taxanes. Our group reported that the ABCC10 single nucleotide polymorphism (SNPs), rs2125739, influences docetaxel cytotoxicity in lung cancer cell lines as well as its side effects in clinical practice. In this study, we investigated whether the rs2125739 variant could affect paclitaxel (PTX) cytotoxicity in lung cancer cell lines. Read More

View Article and Full-Text PDF

Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia.

Recenti Prog Med 2022 Jun;113(6):376-379

Division of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy.

Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease. The therapeutic paradigm of patients with HR-positive HER2-negative metastatic breast cancer has been expanded by the introduction of the inhibitors of cyclin-dependent kinases 4/6. Three compounds, palbociclib, ribociclib, and abemaciclib, have already been approved by the Food and Drug Administration (FDA) for use together with endocrine therapy; abemaciclib is also approved as a single agent. Read More

View Article and Full-Text PDF

Mortality-associated clinical risk factors in patients with febrile neutropenia: A retrospective study.

IJID Reg 2021 Dec 20;1:5-11. Epub 2021 Sep 20.

Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.

Objectives: To determine the predictors for 30-day all-cause mortality in patients with febrile neutropenia (FN) and develop a prediction score.

Methods: The electronic medical records of patients undergoing chemotherapy with FN between 2018 and 2019 were reviewed. Multivariate logistic regression was performed to identify factors associated with 30-day all-cause mortality to develop a parsimonious model. Read More

View Article and Full-Text PDF
December 2021

Neutropenia and Leukopenia After Cross Taper From Quetiapine to Divalproex for the Treatment of Borderline Personality Disorder.

Fed Pract 2022 Apr 11;39(4):182-185. Epub 2022 Apr 11.

Memphis Veterans Affairs Medical Center, Tennessee.

Background: Valproic acid (VPA) and its derivative, divalproex (DVP) can cause various hematologic dyscrasias, the most common being thrombocytopenia. Neutropenia and leukopenia have been reported in isolated cases, most occurring in pediatric patients or patients with epilepsy. We report a case of leukopenia and neutropenia that presented after cross taper from quetiapine to DVP for the treatment of borderline personality disorder. Read More

View Article and Full-Text PDF

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.

J Adv Pract Oncol 2022 May 21;13(4):400-415. Epub 2022 Jun 21.

University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan.

Venetoclax is a potent oral, highly selective small-molecule inhibitor of the antiapoptotic B-cell lymphoma 2 protein approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in treatment-naive patients (in combination with obinutuzumab) or for patients with relapsed/refractory CLL (in combination with rituximab). Venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine, is also approved in the United States for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are ≥ 75 years or have comorbidities that preclude use of intensive induction chemotherapy. Clinical studies of patients with CLL or AML report both hematologic (e. Read More

View Article and Full-Text PDF

Signal Recognition Particle in Human Diseases.

Front Genet 2022 8;13:898083. Epub 2022 Jun 8.

Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, United States.

The signal recognition particle (SRP) is a ribonucleoprotein complex with dual functions. It co-translationally targets proteins with a signal sequence to the endoplasmic reticulum (ER) and protects their mRNA from degradation. If SRP is depleted or cannot recognize the signal sequence, then the Regulation of Aberrant Protein Production (RAPP) is activated, which results in the loss of secretory protein mRNA. Read More

View Article and Full-Text PDF

[Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].

Zhonghua Wei Chang Wai Ke Za Zhi 2022 Jun;25(6):531-538

Department of Radiation Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China School of Medical Imaging, Xuzhou Medical University, Xuzhou 221004, China.

To systematically evaluate the efficacy and safety of total neoadjuvant therapy (TNT) in the comprehensive treatment of locally advanced rectal cancer. Literatures were screened from PubMed, Embase, Web of Science, Cochrane Library, CBM, Wanfang Data, VIP and CNKI from the inception date to May 2021 to collect the randomized controlled clinical trials (RCTs) of TNT followed by total mesorectal excision (TME) versus neoadjuvant chemotherapy (nCRT) followed by TME in the treatment of locally advanced rectal cancer. The data of overall survival, disease-free survival, R0 radical resection rate, pathological complete response (pCR) rate, T downstaging rate, the incidence of adverse events ≥ grade III, including neutropenia, nausea and vomiting, diarrhea, radiation dermatitis and nervous system toxicity, and the morbidity of complications within postoperative 30 days of the two groups were extracted from the included literatures. Read More

View Article and Full-Text PDF

Safety of linezolid, rifampicin, and clindamycin combination therapy in patients with prosthetic joint infection.

Drug Discov Ther 2022 Jun 25. Epub 2022 Jun 25.

Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan.

We investigated adverse events in patients with prosthetic joint infections receiving combination therapy with linezolid, rifampicin, and clindamycin for ≥ 7 days. Twenty-two patients were evaluated. The combination therapy was administered for 15. Read More

View Article and Full-Text PDF

Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire: the MINDSET study.

Eur J Haematol 2022 Jun 26. Epub 2022 Jun 26.

Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.

Objectives: Infections are a major cause of morbidity and mortality in patients with myelodysplastic syndromes (MDS). The objective of the MINDSET study was to evaluate haematologists' management of infection prevention in MDS patients using a case vignette study and to assess the availability of guidelines.

Methods: We conducted a web-based, nationwide survey amongst haematologists in the Netherlands between September and December 2021. Read More

View Article and Full-Text PDF

Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study).

Cancer Med 2022 Jun 25. Epub 2022 Jun 25.

Medical Oncology Department of Zhongshan Hospital affiliated to Fudan University, Shanghai, China.

Purpose: The prognosis of diffuse-type gastric cancer (DGC) is poorer than that of intestinal type, but S-1 is a potential treatment option in DGC. This study explored the maximal tolerated dose (MTD) and the recommended dose for phase II study (RP2D) of nab-paclitaxel combined with S-1 (AS regimen) as adjuvant chemotherapy in stage III DGC.

Methods: Patients with stage III DGC were recruited into this phase I dose-escalation study between July 2019 and June 2020 in Zhongshan Hospital. Read More

View Article and Full-Text PDF

Necrotizing Fasciitis In A Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab.

Am J Case Rep 2022 Jun 25;23:e935584. Epub 2022 Jun 25.

Department of Internal Medicine, BronxCare Hospital, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.

BACKGROUND Necrotizing fasciitis is a life-threatening infection of the deep soft tissues that leads to progressive destruction of the fascia and subcutaneous fat. It typically spreads along the muscle fascia planes because of the relatively poor blood supply. Muscle tissue is usually spared because of its better blood supply. Read More

View Article and Full-Text PDF

Neutropenia in Patients With Clozapine-Treated Schizophrenia: An Effect of Clozapine or a Consequence of SARS-CoV-2 Infection? A Systematic Review.

Am J Ther 2022 Jun 24. Epub 2022 Jun 24.

Universitatea Transilvania, Braşov, Romania; and.

Background: Clozapine is the only approved antipsychotic for treatment-resistant schizophrenia. Despite its therapeutic benefits, it is still widely underused, mainly because of its potential to cause agranulocytosis and neutropenia. Prescribing clozapine in COVID-19-positive patients became more challenging because of this potential side effect. Read More

View Article and Full-Text PDF

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.

Invest New Drugs 2022 Jun 24. Epub 2022 Jun 24.

Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.

This study examined the activity and safety of amrubicin monotherapy among relapsed small-cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus carboplatin and etoposide (AteCE). This retrospective study evaluated patients with relapsed SCLC who were treated with previously AteCE combination therapy followed by amrubicin monotherapy between August 2019 and May 2021. Clinical efficacy and toxicity were analyzed. Read More

View Article and Full-Text PDF

The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome.

Pediatr Nephrol 2022 Jun 24. Epub 2022 Jun 24.

Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo, 157-853, Japan.

Background: Hypogammaglobulinemia is a major adverse effect from rituximab. However, the association between rituximab-induced hypogammaglobulinemia and infection frequency is unknown.

Methods: Patients who received rituximab for complicated nephrotic syndrome between February 2006 and October 2020 were enrolled in this retrospective observational study. Read More

View Article and Full-Text PDF

Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study.

J Antimicrob Chemother 2022 Jun 24. Epub 2022 Jun 24.

Department of Infectious Diseases, University Hospital of Nantes and CIC 1413, Nantes, France.

Background: Early antibiotic discontinuation according to the Fourth European Conference on Infections in Leukaemia (ECIL-4) recommendations is not systematically applied in high-risk neutropenic patients with haematological malignancies.

Methods: A retrospective multicentre observational study was conducted over 2 years to evaluate the safety of early antibiotic discontinuation for fever of unknown origin (FUO) during neutropenia after induction chemotherapy or HSCT, in comparison with a historical cohort. We used Cox proportional hazards models, censored on neutropenia resolution, to analyse factors associated with febrile recurrence. Read More

View Article and Full-Text PDF

Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China.

Front Oncol 2022 7;12:875469. Epub 2022 Jun 7.

Department of Hematology, The First Hospital of Jilin University, Changchun, China.

Objective: To assess the potential benefit of chidamide maintenance therapy after induction treatment in peripheral T-cell lymphoma (PTCL).

Materials And Methods: The clinical data of 48 transplantation-ineligible patients with different PTCL subtypes who received continuous chidamide treatment after first-line therapy were collected. Progression-free survival (PFS), overall survival (OS), and safety were analyzed. Read More

View Article and Full-Text PDF

Infections in Cancer Patients.

Pathogens 2022 Jun 12;11(6). Epub 2022 Jun 12.

Department of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University, IX Wieków Kielc 19A, 25-317 Kielce, Poland.

() is one of the most frequent opportunistic microorganisms causing infections in oncological patients, especially those with neutropenia. Through its ability to adapt to difficult environmental conditions and high intrinsic resistance to antibiotics, it successfully adapts and survives in the hospital environment, causing sporadic infections and outbreaks. It produces a variety of virulence factors that damage host cells, evade host immune responses, and permit colonization and infections of hospitalized patients, who usually develop blood stream, respiratory, urinary tract and skin infections. Read More

View Article and Full-Text PDF

Hemochromatosis Mimicked Gaucher Disease: Role of Hyperferritinemia in Evaluation of a Clinical Case.

Biology (Basel) 2022 Jun 15;11(6). Epub 2022 Jun 15.

Department of Internal Medicine, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Benfratelli, 90127 Palermo, Italy.

Gaucher disease is a disorder of lysosomes caused by a functional defect of the glucocerebrosidase enzyme. The disease is mainly due to mutations in the GBA1 gene, which determines the gradual storage of glucosylceramide substrate in the patient's macrophages. In this paper, we describe the case of a 38-year-old man who clinically presented with hyperferritinemia, thrombocytopenia, leukopenia, anemia and mild splenomegaly; a diagnosis of hemochromatosis was made 10 years earlier. Read More

View Article and Full-Text PDF

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial.

Cancers (Basel) 2022 Jun 17;14(12). Epub 2022 Jun 17.

The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.

Oral metronomic topotecan represents a novel approach to chemotherapy delivery which, in preclinical models, may work synergistically with pazopanib in targeting angiogenesis. A phase I and pharmacokinetic (PK) study of this combination was performed in children with relapsed/refractory solid tumors. Oral topotecan and pazopanib were each administered daily without interruption in 28-day cycles at five dose levels (0. Read More

View Article and Full-Text PDF

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes.

Cancers (Basel) 2022 Jun 8;14(12). Epub 2022 Jun 8.

Department of Cancer Prevention, Medical University of Warsaw, 01-445 Warsaw, Poland.

Background: pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related deaths with increasing incidence and link to the onset of diabetes mellitus (DM). The aim of this study is to describe the prevalence of DM among patients with the diagnosis of PDAC, analyse the association between the occurrence of DM and clinicopathological factors, and detect variables influencing overall survival.

Methods: a retrospective analysis of medical records was performed. Read More

View Article and Full-Text PDF

Dietary Parsley Seed Mitigates Methomyl-Induced Impaired Growth Performance, Hemato-Immune Suppression, Oxidative Stress, Hepato-Renal Damage, and Susceptibility in .

Antioxidants (Basel) 2022 Jun 16;11(6). Epub 2022 Jun 16.

Department of Fish Diseases and Management, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.

The present experiment investigated the potential protective role of parsley () seed meal (PSM) in alleviating methomyl (MET)-adverse impacts on growth, whole-body composition, hematological indicators, hepatorenal function, immune response, oxidative status, and disease resistance to . For this purpose, 225 healthy Nile tilapia () were allotted into five groups (45 fish/group in triplicate). One group was reared in clean water and fed a non-supplemented basal diet, while the other groups were exposed to 20. Read More

View Article and Full-Text PDF

Presumed zonisamide-induced blood dyscrasias in four dogs.

J Vet Emerg Crit Care (San Antonio) 2022 Jun 23. Epub 2022 Jun 23.

Angell Animal Medical Center, Boston, Massachusetts, USA.

Objective: To describe 4 canine cases of presumed zonisamide-induced blood dyscrasias.

Case Summary: From 2007 to 2018 at Angell Animal Medical Center and from 2014 to 2019 at the Cummings School of Veterinary Medicine at Tufts University, 4 dogs presented with febrile neutropenia while being administered zonisamide. No septic focus was found on workup for any of the dogs, and the clinical signs were attributed to an idiosyncratic drug reaction. Read More

View Article and Full-Text PDF

A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2022 May 23. Epub 2022 May 23.

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA. Electronic address:

Purpose: We conducted a phase I study to evaluate the maximum tolerated dose (MTD), safety, and efficacy of trametinib in combination with TAS-102 in patients with chemotherapy-refractory KRAS-mutant, wild-type PIK3CA/PTEN metastatic colorectal cancer (mCRC).

Methods: A 3+3 dose de-escalation single arm phase I clinical trial was performed in patients with chemorefractory mCRC without priorTAS-102 exposure. Patients received fixed dosing of trametinib 2mg oral daily along with de-escalating doses of TAS-102 beginning at 35 mg/m twice daily on days 1-5 and days 8-12 every 28 days. Read More

View Article and Full-Text PDF

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.

J Manag Care Spec Pharm 2022 Jul;28(7):795-802

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville.

It is unknown whether using pegfilgrastim biosimilars is cost saving in a real-world setting. To compare medical costs including pegfilgrastim drug costs and febrile neutropenia (FN) treatment and management costs between pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-cbqv) and originator users for primary prophylaxis of febrile neutropenia. A retrospective cohort study using 2019 IBM MarketScan Commercial and Medicare Supplemental databases was conducted in adult patients with cancer initiating myelosuppressive chemotherapy courses. Read More

View Article and Full-Text PDF

Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients.

Pediatr Rep 2022 Jun 8;14(2):288-292. Epub 2022 Jun 8.

School of Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA.

Myelosuppression, a potential adverse reaction of nafcillin and rifampin, is rarely documented in pediatric populations. The objective of this study is to describe the incidence of myelosuppression in pediatric patients receiving nafcillin or a combination of nafcillin and rifampin therapy. This retrospective chart review identified patients who received nafcillin alone or in combination with rifampin. Read More

View Article and Full-Text PDF

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study.

J Fungi (Basel) 2022 May 29;8(6). Epub 2022 May 29.

Institute of Hematology, Università Cattolica del Sacro Cuore, 20123 Roma, Italy.

The potential drug-drug interactions of midostaurin may impact the choice of antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate the incidence of invasive fungal diseases (IFD) during the treatment of FLT3-mutated AML patients and to correlate it to the different AF prophylaxis strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen patients treated with chemotherapy + midostaurin as induction/reinduction, consolidation or both were enrolled. Read More

View Article and Full-Text PDF

Phagocytosis of Mature Granulocytes by Bone Marrow Macrophages in an Elderly Man with Adult-Onset Primary Autoimmune Neutropenia.

Hematol Rep 2022 May 25;14(2):165-171. Epub 2022 May 25.

Hematology Ohta Clinic, Shinsaibashi, Osaka 5420081, Japan.

Adult-onset primary autoimmune neutropenia (AIN) is an extremely rare but sometimes life-threatening disease. Its pathophysiology is still to be clarified. We describe a case with adult-onset primary AIN with phagocytosis of mature granulocytes by macrophages in bone marrow. Read More

View Article and Full-Text PDF

Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis.

Curr Oncol 2022 Jun 14;29(6):4245-4259. Epub 2022 Jun 14.

Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.

Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. Despite durable responses and sustained remission rates to frontline therapy, CLL is still incurable within standard therapy and eventually relapses. Maintenance therapies aim to achieve deep remission. Read More

View Article and Full-Text PDF

[Encephalitis as neurological complication due dengue].

Rev Chilena Infectol 2022 02;39(1):91-94

UCI Gestión Salud, Medicina Crítica y Cuidados Intensivos, Universidad de Cartagena, Cartagena, Colombia.

We present the case of a 32-year-old male, previously healthy, with a 5-day history of fever, frontal-occipital headache, retro-ocular pain, rash, petechiae, myalgia, arthralgia, and abdominal pain. Blood tests with leukopenia, severe thrombocytopenia, transaminitis, long clotting times. Severe dengue with associated coagulopathy was diagnosed, indicating transfer to ICU. Read More

View Article and Full-Text PDF
February 2022

[Neutropenic enterocolitis in the pediatric cancer patient].

Rev Chilena Infectol 2022 02;39(1):59-69

Hospital Clínico San Borja Arriarán, Chile.

Neutropenic enterocolitis (NEC) is a heterogeneous disease of the gastrointestinal tract with systemic response, that corresponds to a severe and life-threatening clinical condition in immunocompromised patients, especially in childhood cancer. The pathologic features are poorly understood, although its multifactorial cause of NEC is well established and it is associated with the cytotoxic effects of the chemotherapy agents used and recognized by the classic triad of fever, neutropenia, and abdominal pain, secondary to gastrointestinal injuries that alters mucosal permeability and helps intramural bacterial invasion. NEC is truly a clinical challenge that requires an early diagnosis and a multidisciplinary approach including basic laboratory and imagological tests in high complexity centers. Read More

View Article and Full-Text PDF
February 2022